For John

In memory of my little brother and best friend, John.

For John was created in honor of John Gegen. Researchers have spent decades building knowledge about osteosarcoma, often in separate labs, trials and journals. I’m leveraging frontier AI models to bring that work together, connect the dots between studies, and carry the connections to the people who can test them.

Not medical advice. Nothing here is a recommendation about any patient's care. Findings are leads for researchers to check, not conclusions.

What we found

Each finding carries a label for how solid it is: Confirmed (checked against the original source), Lead (supported, but needs a scientist to test it), or Hypothesis (a reasoned idea, not yet tested).

Kinase-inhibitor pills: active, but briefly

Patients free of progression about four months into treatment, relapsed osteosarcoma

Pooled from published trials and registry results, weighted by patients. The red line is the historical benchmark of about 12%.

Show as a table
TreatmentPatients4-month rate

What we're asking

    If you work on osteosarcoma, or on any of the targets above, and something here is wrong or useful, please open an issue on GitHub. Corrections are as valuable as confirmations.

    How this was made

    Read the full methods and limitations

    The reports